The team leader is Jun Takahasi, teacher at the university's Center for iPS Cell Research and Application, has gotten government endorsement and is requesting a few patients to take an interest in the trial to be led at Kyoto University Hospital, as per sources near the issue.
A Kyoto University research team said Monday it will begin this week a clinical test using induced pluripotent stem cells to treat Parkinson's disease, in what will be the world's first application of iPS to the progressive neurological disorder. No tumors has been identified that could develop cancer brain over two years of observations. Lack of the neurotransmitter dopamine produced by the brain cells, reduces the conductivity of the neurons, leading to the loss of control over dvigatelnoy by human activity.
Takahashi and his colleagues will inject dopamine-producing neural progenitor cells-derived from (iPSCs) from healthy adult donors-into Parkinson's patients' brains.More news: Asia’s June Iran oil imports hit seven-month low
But the new research aims to actively reverse the disease. Approximately 5 million cells will be injected into the patients' striatum (in red above), the primary brain region implicated in the disease.
Last August, a lab run by Jun Takahashi found that monkeys with Parkinson's disease symptoms had significant improvement over two years after being transplanted neurons prepared from human iPS cells.
The neurosurgeon plans to test the stem cell Parkinson's treatment on seven patients and transplant about five million iPS cells each into a specific area of the brain known as the putamen - a large, round structure located at the base of the forebrain and which regulates limb movement, explains Healthline.More news: Google Clock now supports Spotify for alarms
As an added precaution against transplant rejection, the Parkinson's patients will also receive a drug called tacrolimus, created to suppress the immune response and prevent the body from attacking the iPS cells.
In Parkinson's disease, the dopaminergic neurons cells degenerate, resulting in decreased dopamine production.
Worldwide, about 10 million people have the illness, according to the Parkinson's Disease Foundation.More news: Fortnite's Guided Missile & Jetpack Return In v5.10
In other planned studies using iPS cells, a research team at Keio University will treat spinal cord injuries, while another team at Kyoto University has plans to create blood platelets, which help the body form blood clots.